Rivus Pharma is a healthcare startup that focuses on addressing obesity, a primary driver of cardio-metabolic diseases. The company operates in the pharmaceutical market, targeting a large segment of the American population suffering from obesity-related health issues.

Rivus Pharma's business model revolves around the development and commercialization of Controlled Metabolic Accelerators (CMAs). These are oral, small molecule therapies designed to improve cellular metabolism. They work by harnessing a natural metabolic process in mitochondria, the powerhouse of cells, to increase the breakdown of fats and sugars and increase resting energy expenditure. This results in decreased fat throughout the body while maintaining skeletal muscle mass, which is crucial to minimize fat regain and reduce cardio-metabolic risk.

The company's leading product, HU6, a first-in-class CMA, has shown promising results in a Phase 2 clinical trial, improving disease markers of blood pressure, inflammation, and glycemic control. Rivus Pharma's revenue comes from the sales of these therapies, which are being studied to treat obesity and improve the health of millions.

In simple terms, Rivus Pharma is a company that creates medicines to help people lose weight in a healthy way, targeting the fat in the body while preserving muscle mass. Their products are intended to help reduce the risk of heart disease, type 2 diabetes, and other health issues related to obesity.

Keywords: Rivus Pharma, Obesity, Cardio-metabolic diseases, Controlled Metabolic Accelerators (CMAs), Cellular Metabolism, Mitochondria, Fat Reduction, Muscle Preservation, HU6, Pharmaceutical Market.